MedPath

Can Volumetric modulated arc radiotherapy spare the thyroid gland in the treatment of head and neck cancers

Phase 2
Completed
Conditions
Health Condition 1: C01- Malignant neoplasm of base of tongueHealth Condition 2: C13- Malignant neoplasm of hypopharynxHealth Condition 3: C10- Malignant neoplasm of oropharynxHealth Condition 4: C02- Malignant neoplasm of other and unspecified parts of tongueHealth Condition 5: C321- Malignant neoplasm of supraglottis
Registration Number
CTRI/2020/06/025863
Lead Sponsor
ONE
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
26
Inclusion Criteria

1 Squamous cell carcinoma of the oral cavity,

oropharynx, supraglottic larynx and hypopharynx

2 Locally advanced disease (Stage III , IV)

3 Histological proof of malignancy

4 Patients treated with radical intent

Exclusion Criteria

1. Patients with Nasopharyngeal malignancies

2. Patients who have thyroid dysfunction or are known to have thyroid dysfunction during baseline investigations

3. Prior radiotherapy, chemotherapy or head and neck surgery

4.Thyroid malignancies or tumours involving the thyroid gland

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath